CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

Core Insights - CID-103 is identified as a potential best-in-class, clinical stage anti-CD38 monoclonal antibody [1] - The safety profile observed in the first four dose cohorts supports continued development of CID-103 [1] - No serious adverse events or dose-limiting toxicities have been reported during the study [1] Company Updates - CASI Pharmaceuticals, Inc. is focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases [1] - The Safety Monitoring Committee (SMC) has completed its review of cohort 4 (600 mg target dose) and is continuing its assessment of the first three cohorts in the Phase 1 study [1] - The SMC has recommended that the trial continue, allowing for dose escalation to cohort 5 (900 mg target dose) as per the protocol design [1]